Artemis Medicare Services Future Growth
Future criteria checks 6/6
Artemis Medicare Services is forecast to grow earnings and revenue by 47.1% and 35.4% per annum respectively. EPS is expected to grow by 47.3% per annum. Return on equity is forecast to be 20% in 3 years.
Key information
47.1%
Earnings growth rate
47.3%
EPS growth rate
Healthcare earnings growth | 25.6% |
Revenue growth rate | 35.4% |
Future return on equity | 20.0% |
Analyst coverage | Low |
Last updated | 11 Jul 2024 |
Recent future growth updates
No updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Artemis Medicare Services Limited's (NSE:ARTEMISMED) CEO For Now
Jul 18Artemis Medicare Services Limited's (NSE:ARTEMISMED) P/E Is Still On The Mark Following 31% Share Price Bounce
Jul 16After Leaping 27% Artemis Medicare Services Limited (NSE:ARTEMISMED) Shares Are Not Flying Under The Radar
Apr 13Artemis Medicare Services (NSE:ARTEMISMED) Has A Pretty Healthy Balance Sheet
Jun 14Artemis Medicare Services (NSE:ARTEMISMED) Has A Somewhat Strained Balance Sheet
Mar 15Capital Allocation Trends At Artemis Medicare Services (NSE:ARTEMISMED) Aren't Ideal
Aug 31Is Artemis Medicare Services (NSE:ARTEMISMED) A Risky Investment?
Jul 30Artemis Medicare Services (NSE:ARTEMISMED) Is Reinvesting At Lower Rates Of Return
May 13Returns On Capital At Artemis Medicare Services (NSE:ARTEMISMED) Paint A Concerning Picture
Jan 11Artemis Medicare Services (NSE:ARTEMISMED) Has A Pretty Healthy Balance Sheet
Dec 10There Are Reasons To Feel Uneasy About Artemis Medicare Services' (NSE:ARTEMISMED) Returns On Capital
Sep 11Artemis Medicare Services (NSE:ARTEMISMED) Has A Somewhat Strained Balance Sheet
Jul 01There Are Reasons To Feel Uneasy About Artemis Medicare Services' (NSE:ARTEMISMED) Returns On Capital
May 11We Think Artemis Medicare Services (NSE:ARTEMISMED) Is Taking Some Risk With Its Debt
Mar 16Is Artemis Medicare Services (NSE:ARTEMISMED) Likely To Turn Things Around?
Jan 22Is Artemis Medicare Services (NSE:ARTEMISMED) A Risky Investment?
Nov 13Market Still Lacking Some Conviction On Artemis Medicare Services Limited (NSE:ARTEMISMED)
Jul 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 18,450 | 1,330 | N/A | N/A | 1 |
3/31/2025 | 13,690 | 850 | N/A | N/A | 1 |
3/31/2024 | 8,786 | 491 | 363 | 1,089 | N/A |
12/31/2023 | 8,486 | 456 | N/A | N/A | N/A |
9/30/2023 | 8,173 | 445 | -174 | 1,153 | N/A |
6/30/2023 | 7,797 | 400 | N/A | N/A | N/A |
3/31/2023 | 7,374 | 386 | -193 | 1,272 | N/A |
12/31/2022 | 6,916 | 412 | N/A | N/A | N/A |
9/30/2022 | 6,482 | 373 | -289 | 788 | N/A |
6/30/2022 | 5,997 | 363 | N/A | N/A | N/A |
3/31/2022 | 5,548 | 318 | -494 | 595 | N/A |
12/31/2021 | 5,345 | 313 | N/A | N/A | N/A |
9/30/2021 | 5,147 | 301 | -250 | 530 | N/A |
6/30/2021 | 4,680 | 221 | N/A | N/A | N/A |
3/31/2021 | 4,084 | 65 | -72 | 273 | N/A |
12/31/2020 | 4,177 | -19 | N/A | N/A | N/A |
9/30/2020 | 4,370 | -16 | 246 | 346 | N/A |
6/30/2020 | 4,920 | 38 | N/A | N/A | N/A |
3/31/2020 | 5,650 | 198 | 301 | 561 | N/A |
12/31/2019 | 5,667 | 211 | N/A | N/A | N/A |
3/31/2019 | 5,465 | 205 | -168 | 404 | N/A |
3/31/2018 | 5,028 | 268 | 106 | 719 | N/A |
3/31/2017 | 4,590 | 271 | N/A | 579 | N/A |
3/31/2016 | 4,018 | 216 | N/A | 205 | N/A |
3/31/2015 | 3,675 | 186 | N/A | 528 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARTEMISMED's forecast earnings growth (47.1% per year) is above the savings rate (6.7%).
Earnings vs Market: ARTEMISMED's earnings (47.1% per year) are forecast to grow faster than the Indian market (15.9% per year).
High Growth Earnings: ARTEMISMED's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ARTEMISMED's revenue (35.4% per year) is forecast to grow faster than the Indian market (9.6% per year).
High Growth Revenue: ARTEMISMED's revenue (35.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARTEMISMED's Return on Equity is forecast to be high in 3 years time (20%)